Form 8-K - Current report:
SEC Accession No. 0001104659-25-009813
Filing Date
2025-02-06
Accepted
2025-02-05 21:51:21
Documents
20
Period of Report
2025-02-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm255441d1_8k.htm   iXBRL 8-K 29058
2 EXHIBIT 1.1 tm255441d1_ex1-1.htm EX-1.1 209022
3 EXHIBIT 5.1 tm255441d1_ex5-1.htm EX-5.1 14101
4 EXHIBIT 99.1 tm255441d1_ex99-1.htm EX-99.1 11639
5 EXHIBIT 99.2 tm255441d1_ex99-2.htm EX-99.2 11853
6 GRAPHIC tm255441d1_ex5-1img001.jpg GRAPHIC 6424
7 GRAPHIC tm255441d1_ex99-1img002.jpg GRAPHIC 15372
8 GRAPHIC tm255441d1_ex99-2img001.jpg GRAPHIC 7139
  Complete submission text file 0001104659-25-009813.txt   560400

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvct-20250205_lab.xml EX-101.LAB 34240
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvct-20250205_pre.xml EX-101.PRE 22359
11 XBRL TAXONOMY EXTENSION SCHEMA nvct-20250205.xsd EX-101.SCH 3015
22 EXTRACTED XBRL INSTANCE DOCUMENT tm255441d1_8k_htm.xml XML 3652
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41264 | Film No.: 25595197
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)